9EJW | pdb_00009ejw

Fibroblastic reticular cells direct the initiation of T cell responses via CD44.

(2026) Nature 

• PubMed: 41565815 Search on PubMedSearch on PubMed Central
• DOI: https://doi.org/10.1038/s41586-025-09988-8
• Primary Citation of Related Structures:  
  9EJW


• PubMed Abstract: 
  

  The movement of dendritic cells and T cells within secondary lymphoid organs is critical for the development of adaptive immune responses ^1,2 . Central to this process is the fibroblastic reticular cell (FRC) network, which forms a highly organized conduit system that facilitates the movement of and interactions between dendritic cells and T cells ^3-6 . Previous studies have partly characterized how FRCs support these interactions ^7,8 . However, the molecular mechanisms that operate under physiological conditions remain unknown. Here we show that the viral protein m11, encoded by the herpesvirus murine cytomegalovirus (CMV), inhibits antiviral immunity by targeting the FRC network and interfering with a critical function of cellular CD44. We found that m11 binds to CD44 and established that m11 perturbs the molecular interactions of CD44 with its natural ligand, hyaluronic acid. The interaction of m11 with CD44 impairs the trafficking of dendritic cells within the spleen, thereby impeding efficient priming of naive T cells and the initiation of antiviral CD8 T cell responses. The targeting of CD44 by CMV reveals CD44 as a molecule that is essential to the functioning of the FRC network and uncovers a previously unrecognized stroma-based mechanism that is critical for the generation of effective T cell responses.

   View More

---

Organizational Affiliation: 
• Infection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Centre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, Australia.
Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Audax Biosciences, Melbourne, Victoria, Australia.
Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Lyman BioPharma Consulting, Seattle, WA, USA.
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Institute of Infection and Immunity, Cardiff University, School of Medicine, Cardiff, UK.
Infection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia. chris.andoniou@monash.edu.
Centre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, Australia. chris.andoniou@monash.edu.
Infection and Immunity Program and Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia. mariapia.degli-esposti@monash.edu.
Centre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, Australia. mariapia.degli-esposti@monash.edu.
 View More